Page last updated: 2024-12-10

2-hydroxyatorvastatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-hydroxyatorvastatin: an atorvastatin metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129734920
MeSH IDM0508946

Synonyms (1)

Synonym
2-hydroxyatorvastatin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method was used for pharmacokinetic study of ATV and HATV."( Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study.
Barrett, B; Borek-Dohalský, V; Huclová, J; Jelínek, I; Nemec, B; Ulc, I, 2006
)
0.33
"290 Koreans were genotyped for SLCO1B1, ABCB1 and CYP3A5, and 28 subjects were selected for the pharmacokinetic study."( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010
)
0.36
" In lactone forms, no significant pharmacokinetic difference was found among the genotypes."( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010
)
0.36
"This study shows that the SLCO1B1*15 allele may be associated with the individual difference in the AUC0-infinity of atorvastatin whereas the ABCB1 TT-TT diplotype may affect the elimination half-life of the drug in the Korean population."( Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA, 2010
)
0.36
" The absence of a significant pharmacokinetic interaction between fenofibrate and atorvastatin is consistent with recent results showing no difference in safety profile between atorvastatin as monotherapy or in combination with fenofibric acid."( Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Our analysis suggested that patients carrying one variant allele for the rs2622604 polymorphism (ABCG2) show a 55% (95% confidence interval: 16-131%) increase in atorvastatin oral bioavailability relative to the value in individuals without the variant allele."( Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
Aarons, L; Galetin, A; Guo, Y; Hall, S; Tsamandouras, N; Wendling, T, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" Blood samples were collected scheduled intervals for 24 hours after the last dosing to determine plasma concentrations of atorvastatin acid, atorvastatin lactone, 2-hydroxy atorvastatin acid, and 2-hydroxy atorvastatin lactone."( The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Cho, JY; Jang, IJ; Kim, SE; Kim, TE; Lee, MG; Shin, KH; Shin, SG; Song, IS; Yoon, SH; Yu, KS, 2011
)
0.37
" The model developed may be of clinical importance to guide dosing recommendations tailored specifically for the Japanese."( Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
Aarons, L; Galetin, A; Guo, Y; Hall, S; Tsamandouras, N; Wendling, T, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's5 (27.78)29.6817
2010's12 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (44.44%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (55.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]